Detalles de la búsqueda
1.
Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer.
Cancer Sci;
115(5): 1656-1664, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38450844
2.
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.
Br J Cancer;
2024 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38822146
3.
Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
Oncologist;
29(5): e681-e689, 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38241181
4.
Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK-rearranged lung cancer.
Cancer Sci;
114(1): 164-173, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36086904
5.
High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.
Cancer Sci;
114(2): 606-618, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36169649
6.
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.
Cancer Immunol Immunother;
72(6): 1699-1707, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36617602
7.
Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer.
Support Care Cancer;
31(5): 308, 2023 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37115357
8.
Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Oncologist;
25(3): 208-e417, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162814
9.
Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801.
Oncologist;
25(8): e1146-e1157, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32385918
10.
Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
Oncologist;
24(8): 1033-e617, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31040252
11.
A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Oncologist;
24(4): 459-e131, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30578309
12.
Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
Oncologist;
24(5): 593-e170, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30651400
13.
Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer.
Invest New Drugs;
37(2): 291-296, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30121935
14.
Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
Invest New Drugs;
36(5): 903-910, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29846848
15.
The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
BMC Cancer;
18(1): 1241, 2018 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30537950
16.
Use of Phosphatidylcholine for Correction of Festoons.
Dermatol Surg;
49(7): 717, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37184452
17.
Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report.
BMC Pulm Med;
18(1): 193, 2018 Dec 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30541518
18.
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
Cancer Sci;
108(1): 53-60, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27783866
19.
Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
Cancer Sci;
108(7): 1378-1385, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28474864
20.
Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation.
Cancer Sci;
108(4): 696-703, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28182302